Clinical Status: Temporarily Suspended

NCT05263284 is a Phase 1 trial conducted at City of Hope Medical Center under the support of the NCI (National Cancer Institute), with Dr. Vinod Pullarkat, a hematology specialist, as the principal investigator. The study design involves administering 8-chloroadenosine (8-Cl-Ado) intravenously over 4 hours on days 1-5, followed by oral administration of venetoclax (Venclexta) on days 1-28, with a 28-day cycle repeated for a maximum of 4 cycles. Initiated in December 2022, the trial is currently in a 'Suspended' state as of April 2026, with patient enrollment halted. A previous Phase 1 study of 8-Cl-Ado alone (NCT02509546) established an RP2D of 400 mg/m² in 12 patients but failed to achieve complete remission (CR). Grade 3 or higher cardiac toxicity (arrhythmia, QTc prolongation) was reported as a major non-hematological adverse event, suggesting that a review of the safety profile is a key reason for the temporary suspension.

Dual Mechanism Synergy: rRNA Inhibition + BCL-2 Blockade

8-Cl-Ado is a ribosyl nucleoside analog that inhibits RNA polymerase I recruitment to rDNA by degrading the transcription initiation factor TIF-IA via HDM2-mediated ubiquitination, leading to depletion of intracellular ATP. However, single-agent administration can paradoxically increase fatty acid oxidation (FAO) and oxidative phosphorylation (OXPHOS) due to p53 activation, limiting its anti-leukemic efficacy. Venetoclax, by inhibiting BCL-2, simultaneously blocks the FAO and OXPHOS pathways, providing a strategy to attack the metabolic vulnerabilities of leukemia stem cells (LSCs) from two angles. A preclinical study by Hoang et al., published in the journal Cancers in 2022 (PMC8946614), demonstrated downregulation of rRNA synthesis genes, mitochondrial fragmentation, and increased apoptosis in both primary and relapsed/refractory AML samples.

Competitive Landscape and Market Dynamics

The market for relapsed/refractory AML therapies is projected to grow from USD 4.28 billion in 2026 to USD 10.64 billion in 2035 (CAGR of 10.64%). The market for venetoclax as a single agent is also expanding, from USD 1.34 billion in 2025 to USD 2.43 billion in 2033 (CAGR of 12.92%), with joint sales by AbbVie (ABBV) and Genentech (Roche). FDA-approved targeted therapies include gilteritinib (Xospata, FLT3), ivosidenib (Tibsovo, IDH1), enasidenib (Idhifa, IDH2), and olutasidenib (Rezlidhia, IDH1). Notably, revumenib (Revuforj, Syndax Pharmaceuticals), a menin inhibitor approved in 2024-2025, has achieved CR rates of 77-89% in NPM1-mutated/KMT2A-rearranged AML, emerging as a next-generation standard of care, and subsequent menin inhibitor pipelines such as ziftomenib, bleximenib, and enzomenib are also rapidly accumulating clinical data.

Development Prospects and Risks

8-Cl-Ado is an academic-led project with City of Hope holding the IND, and it is operated with NCI funding without a commercial partner. The fact that the previous Phase 1 study only showed a temporary decrease in peripheral blood blasts and no bone marrow CR (Cancer journal, March 2024, co-authored by Pullarkat and Gandhi), and that the combination Phase 1 trial has also been temporarily suspended, increases the development uncertainty. However, the fact that it targets rRNA synthesis inhibition, a mechanism distinct from existing targeted therapies (FLT3, IDH, menin inhibitors), in patients who are refractory to venetoclax plus azacitidine is a clear differentiating factor. Upon clinical resumption, DLT (dose-limiting toxicity) and initial response rate data will be the key determinants of its licensing value.